CA2693845C - Ophthalmic lens materials containing chromophores that absorb both uv and short wavelength visible light - Google Patents
Ophthalmic lens materials containing chromophores that absorb both uv and short wavelength visible light Download PDFInfo
- Publication number
- CA2693845C CA2693845C CA2693845A CA2693845A CA2693845C CA 2693845 C CA2693845 C CA 2693845C CA 2693845 A CA2693845 A CA 2693845A CA 2693845 A CA2693845 A CA 2693845A CA 2693845 C CA2693845 C CA 2693845C
- Authority
- CA
- Canada
- Prior art keywords
- ophthalmic device
- device material
- chromophore
- chromophores
- short wavelength
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Abstract
To obtain polymeric lens materials that absorb both UV and short wavelength visible light, it is common to add separate UV-absorbing and short wavelength light-absorbing chromophores to the polymeric materials. However, having a single chromophore that absorbs both can reduce the number of components added to the lens material and reduce disruption to the primary polymer chain structure of the lens. The present invention relates to chromophores that absorb both UV and short wavelength visible light. The chromophores are particularly suitable for use in intraocular lens materials. The chromophores of the present invention relate to the formula: (see above formula) wherein A=H or CH3; X=O or NH; n=2-6; m=0-6; and R=H, C1-C4 alkyl, or C1-C4 alkoxy.
Description
OPHTHALMIC LENS MATERIALS CONTAINING CHROMOPHORES THAT
ABSORB BOTH UV AND SHORT WAVELENGTH VISIBLE LIGHT
Field of the Invention This invention is directed to chromophores. In particular, this invention relates to chromophores that absorb both UV and short wavelength light.
Background of the Invention Many UV light absorbers are known as ingredients for polymeric materials used to make ophthalmic lenses. UV absorbers are preferably covalently bound to the polymeric network of the lens material instead of 1s simply physically entrapped in the material to prevent the absorber from migrating, phase separating or leaching out of the lens material. Such stability is particularly important for implantable ophthalmic lenses, especially intraocular lenses (IOLs), where the leaching of the UV absorber may present both toxicological issues and lead to the loss of UV blocking activity in the implant.
Numerous copolymerizable benzatriazole, benzophenone and triazine UV absorbers are known. Many of these UV absorbers contain conventional olefinic polymerizable groups, such as methacrylate, acrylate, methacrylamide, acrylamide or styrene groups. Copolymerization with other ingredients in the lens materials, typically with a radical initiator, incorporates the UV absorbers into the resulting polymer chain. Incorporation of additional functional groups, on a UV absorber may influence one or more of the UV
absorber's UV absorbing properties, solubility or reactivity. If the UV
absorber does not have sufficient solubility in the remainder of the ophthalmic lens material ingredients or polymeric lens material, the UV absorber may coalesce into domains that could interact with light and result in decreased optical clarity of the lens.
Examples of polymeric ophthalmic lens materials that incorporate UV
absorbers can be found in U.S. Patent Nos. 5,290,892; 5,331,073 and 5,693,095.
Likewise, copolymerizable short wavelength light absorbing chromophores are known as ingredients for polymeric materials used to make ophthalmic lenses. Blue-light absorbing chromophores include those disclosed in U.S. Patent Nos. 5,470,932 and 5,543,504.
In order to obtain polymeric lens materials that absorb both UV and short wavelength visible light (e.g., 400 - 500 nm), it is common to add separate UV-absorbing and short wavelength light-absorbing chromophores to the polymeric materials. For example, the AcrySof Natural IOL product, which is commercially available from Alcon Laboratories, Inc., contains a UV
1s absorber and a blue-light absorber.
Having a single chromophore that absorbs both UV and short wavelength visible light would be advantageous. Such a single chromophore would reduce the number of components that are added to a lens material formulation and reduce disruption to the primary polymer chain structure produced by the lens formulation's primary monomer constituents.
Summary of the Invention The present invention provides chromophores that absorb both UV and short wavelength visible light. These chromophores are suitable for use in ophthalmic lenses, including contact lenses. They are particularly useful in implantable lenses, such as IOLs.
Detailed Description of the Invention Unless indicated otherwise, all ingredient amounts expressed in percentage terms are presented as % w/w.
ABSORB BOTH UV AND SHORT WAVELENGTH VISIBLE LIGHT
Field of the Invention This invention is directed to chromophores. In particular, this invention relates to chromophores that absorb both UV and short wavelength light.
Background of the Invention Many UV light absorbers are known as ingredients for polymeric materials used to make ophthalmic lenses. UV absorbers are preferably covalently bound to the polymeric network of the lens material instead of 1s simply physically entrapped in the material to prevent the absorber from migrating, phase separating or leaching out of the lens material. Such stability is particularly important for implantable ophthalmic lenses, especially intraocular lenses (IOLs), where the leaching of the UV absorber may present both toxicological issues and lead to the loss of UV blocking activity in the implant.
Numerous copolymerizable benzatriazole, benzophenone and triazine UV absorbers are known. Many of these UV absorbers contain conventional olefinic polymerizable groups, such as methacrylate, acrylate, methacrylamide, acrylamide or styrene groups. Copolymerization with other ingredients in the lens materials, typically with a radical initiator, incorporates the UV absorbers into the resulting polymer chain. Incorporation of additional functional groups, on a UV absorber may influence one or more of the UV
absorber's UV absorbing properties, solubility or reactivity. If the UV
absorber does not have sufficient solubility in the remainder of the ophthalmic lens material ingredients or polymeric lens material, the UV absorber may coalesce into domains that could interact with light and result in decreased optical clarity of the lens.
Examples of polymeric ophthalmic lens materials that incorporate UV
absorbers can be found in U.S. Patent Nos. 5,290,892; 5,331,073 and 5,693,095.
Likewise, copolymerizable short wavelength light absorbing chromophores are known as ingredients for polymeric materials used to make ophthalmic lenses. Blue-light absorbing chromophores include those disclosed in U.S. Patent Nos. 5,470,932 and 5,543,504.
In order to obtain polymeric lens materials that absorb both UV and short wavelength visible light (e.g., 400 - 500 nm), it is common to add separate UV-absorbing and short wavelength light-absorbing chromophores to the polymeric materials. For example, the AcrySof Natural IOL product, which is commercially available from Alcon Laboratories, Inc., contains a UV
1s absorber and a blue-light absorber.
Having a single chromophore that absorbs both UV and short wavelength visible light would be advantageous. Such a single chromophore would reduce the number of components that are added to a lens material formulation and reduce disruption to the primary polymer chain structure produced by the lens formulation's primary monomer constituents.
Summary of the Invention The present invention provides chromophores that absorb both UV and short wavelength visible light. These chromophores are suitable for use in ophthalmic lenses, including contact lenses. They are particularly useful in implantable lenses, such as IOLs.
Detailed Description of the Invention Unless indicated otherwise, all ingredient amounts expressed in percentage terms are presented as % w/w.
2 The chromophores of the present invention are represented by the formula C"X
A '~CH2 n / N1~1 O N N
R
m / -N=N
s OH
wherein A = H or CH3;
X = 0 or NH;
n=2-6;
m=0-6;and R H, Cl - C4 alkyl, or C, - C4 alkoxy.
A preferred chromophore of the present invention has is A = CH3;
X=NH;
n=2;
m = 0; and R=CH3.
The synthesis of the chromophores of the present invention is described below. (Scheme 1). 2-Amino-4-(2-amino-ethyl)-phenol (1) is synthesized in 3 steps from 4-methoxyphenylacetonitrile (Macchia, B.;
Macchia, M.; Manera, C.; Martinotti, E.; Nencetti, S.; Orlandini, E.;
Rossello, A.; Scatizzi, R. Eur. J. Med. Chem. 1995, 30, 869). This is followed by aryl diazonium salt formation at pH 1 (Kornblum, N.; Iffland, D. C. J. Am. Chem.
A '~CH2 n / N1~1 O N N
R
m / -N=N
s OH
wherein A = H or CH3;
X = 0 or NH;
n=2-6;
m=0-6;and R H, Cl - C4 alkyl, or C, - C4 alkoxy.
A preferred chromophore of the present invention has is A = CH3;
X=NH;
n=2;
m = 0; and R=CH3.
The synthesis of the chromophores of the present invention is described below. (Scheme 1). 2-Amino-4-(2-amino-ethyl)-phenol (1) is synthesized in 3 steps from 4-methoxyphenylacetonitrile (Macchia, B.;
Macchia, M.; Manera, C.; Martinotti, E.; Nencetti, S.; Orlandini, E.;
Rossello, A.; Scatizzi, R. Eur. J. Med. Chem. 1995, 30, 869). This is followed by aryl diazonium salt formation at pH 1 (Kornblum, N.; Iffland, D. C. J. Am. Chem.
3 Soc. 1949, 71, 2137) to yield 4-(2-amino-ethyl)-2-azido-phenol (2). Aryl alkyne (4) is available in 2 steps from 2-bromo-4-methylphenol and o-toluidine. This is then combined with an equimolar amount of 4-(2-amino-ethyl)-2-azido-phenol (2) and catalytic CuBr to produce 1,2,3-trizaole (5).
The free amine is then reacted with methacrylic anhydride to produce polymerizable chromophore (6). Alternatively, (5) can be reacted with 4-vinylbenzoic acid using carbodiimide coupling to produce a vinyl-functional chromophore.
The free amine is then reacted with methacrylic anhydride to produce polymerizable chromophore (6). Alternatively, (5) can be reacted with 4-vinylbenzoic acid using carbodiimide coupling to produce a vinyl-functional chromophore.
4
5 PCT/US2008/072406 Scheme 1.
Br CH30 ~ OH
~ 1) (trimethylsilyl)acetylene / CN PdCIZ(PPh3)Z, Cul 1/1 Et3N/dioxane 2) KF, MeOH
3 steps (Eur J Med Chem 1995, 30, 869) CH3 CH3 ~
(3) ~ / + H2N ~ /
~ OH /
(1) OH
HZN / NHZ NaNOZ/HCI
pH -2 1) NaNO2/HCI, pH _1, 0 C 0 C
2) NaN3 CH3 + N=N ~ ~
(2) (4) CuBr, PMDETA
/
N ~ I H3C
N ~ N,N ~
N OH
I
HzN ~OH ~ (5) o O
I Nc NN OH N (6) ~4N &-OH
The chromophores of the present invention are particularly suitable for use in IOLs. IOL materials will generally contain from 0.1 to 5%(w/w) of a chromophore of the present invention. Preferably, IOL materials will contain from 0.5 to 3 % (w/w) of a chromophore of the present invention. Such device materials are prepared by copolymerizing the chromophores of the present invention with other ingredients, such as device-forming materials and cross-linking agents.
Many device-forming monomers are known in the art and include both acrylic and silicone-containing monomers among others. See, for example, U.S. Nos. 7,101,949; 7,067,602; 7,037,954; 6,872,793 6,852,793; 6,846,897;
Br CH30 ~ OH
~ 1) (trimethylsilyl)acetylene / CN PdCIZ(PPh3)Z, Cul 1/1 Et3N/dioxane 2) KF, MeOH
3 steps (Eur J Med Chem 1995, 30, 869) CH3 CH3 ~
(3) ~ / + H2N ~ /
~ OH /
(1) OH
HZN / NHZ NaNOZ/HCI
pH -2 1) NaNO2/HCI, pH _1, 0 C 0 C
2) NaN3 CH3 + N=N ~ ~
(2) (4) CuBr, PMDETA
/
N ~ I H3C
N ~ N,N ~
N OH
I
HzN ~OH ~ (5) o O
I Nc NN OH N (6) ~4N &-OH
The chromophores of the present invention are particularly suitable for use in IOLs. IOL materials will generally contain from 0.1 to 5%(w/w) of a chromophore of the present invention. Preferably, IOL materials will contain from 0.5 to 3 % (w/w) of a chromophore of the present invention. Such device materials are prepared by copolymerizing the chromophores of the present invention with other ingredients, such as device-forming materials and cross-linking agents.
Many device-forming monomers are known in the art and include both acrylic and silicone-containing monomers among others. See, for example, U.S. Nos. 7,101,949; 7,067,602; 7,037,954; 6,872,793 6,852,793; 6,846,897;
6,806,337; 6,528,602; and 5,693,095. In the case of IOLs, any known IOL
device material is suitable for use in the compositions of the present invention. Preferably, the ophthalmic device materials comprise an acrylic or methacrylic device-forming monomer. More preferably, the device-forming O
~ C~Y~B~O A
D
/
monomers comprise a monomer of formula [II]:
[Ill where in formula [II]:
A is H, CH3, CH2CH3, or CH2OH;
B is (CH2)m or [O(CH2)2]Z;
C is (CH2),;
mis0-6;
z is 1 - 10;
Y is nothing, 0, S, or NR', provided that if Y is 0, S, or NR', then B is (CH2)m;
R' is H, CH3, Cn,H2n'+1 (n'=1-10), iso-OC3H7, C6H5, or CH2C6H5;
w is 0 - 6, provided that m + w 58; and D is H, Cl - C4 alkyl, Cl - C4 alkoxy, C6H5, CH2C6H5 or halogen.
Preferred monomers of formula [II] are those wherein A is H or CH3, B
is (CH2)m, m is 1 - 5, Y is nothing or 0, w is 0- 1, and D is H. Most preferred are benzyl methacrylate; 2-phenylethyl methacrylate; 4-phenylbutyl methacrylate; 5-phenylpentyl methacrylate; 2-benzyloxyethyl methacrylate;
and 3-benzyloxypropyl methacrylate; and their corresponding acrylates.
Monomers of formula [II] are known and can be made by known methods. For example, the conjugate alcohol of the desired monomer can be combined in a reaction vessel with methyl methacrylate, tetrabutyl titanate (catalyst), and a polymerization inhibitor such as 4-benzyloxy phenol. The vessel can then be heated to facilitate the reaction and distill off the reaction by-products to drive the reaction to completion. Alternative synthesis schemes involve adding methacrylic acid to the conjugate alcohol and catalyzing with a carbodiimide or mixing the conjugate alcohol with methacryloyl chloride and a base such as pyridine or triethylamine.
Device materials generally comprise a total of at least about 75%, preferably at least about 80%, of device-forming monomers.
In addition to a chromophore of the present invention and a device-forming monomer, the device materials of the present invention generally comprise a cross-linking agent. The cross-linking agent used in the device materials of this invention may be any terminally ethylenically unsaturated compound having more than one unsaturated group. Suitable cross-linking agents include, for example: ethylene glycol dimethacrylate; diethylene glycol dimethacrylate; allyl methacrylate; 1,3-propanediol dimethacrylate; 2,3-propanediol dimethacrylate; 1,6-hexanediol dimethacrylate; 1,4-butanediol dimethacrylate; CH2=C(CH3)C(=O)O-(CH2CH2O)p-C(=O)C(CH3)=CH2 where p = 1- 50; and CH2=C(CH3)C(=O)O(CH2)tO-C(=O)C(CH3)=CH2 where t = 3 -20; and their corresponding acrylates. A preferred cross-linking monomer is
device material is suitable for use in the compositions of the present invention. Preferably, the ophthalmic device materials comprise an acrylic or methacrylic device-forming monomer. More preferably, the device-forming O
~ C~Y~B~O A
D
/
monomers comprise a monomer of formula [II]:
[Ill where in formula [II]:
A is H, CH3, CH2CH3, or CH2OH;
B is (CH2)m or [O(CH2)2]Z;
C is (CH2),;
mis0-6;
z is 1 - 10;
Y is nothing, 0, S, or NR', provided that if Y is 0, S, or NR', then B is (CH2)m;
R' is H, CH3, Cn,H2n'+1 (n'=1-10), iso-OC3H7, C6H5, or CH2C6H5;
w is 0 - 6, provided that m + w 58; and D is H, Cl - C4 alkyl, Cl - C4 alkoxy, C6H5, CH2C6H5 or halogen.
Preferred monomers of formula [II] are those wherein A is H or CH3, B
is (CH2)m, m is 1 - 5, Y is nothing or 0, w is 0- 1, and D is H. Most preferred are benzyl methacrylate; 2-phenylethyl methacrylate; 4-phenylbutyl methacrylate; 5-phenylpentyl methacrylate; 2-benzyloxyethyl methacrylate;
and 3-benzyloxypropyl methacrylate; and their corresponding acrylates.
Monomers of formula [II] are known and can be made by known methods. For example, the conjugate alcohol of the desired monomer can be combined in a reaction vessel with methyl methacrylate, tetrabutyl titanate (catalyst), and a polymerization inhibitor such as 4-benzyloxy phenol. The vessel can then be heated to facilitate the reaction and distill off the reaction by-products to drive the reaction to completion. Alternative synthesis schemes involve adding methacrylic acid to the conjugate alcohol and catalyzing with a carbodiimide or mixing the conjugate alcohol with methacryloyl chloride and a base such as pyridine or triethylamine.
Device materials generally comprise a total of at least about 75%, preferably at least about 80%, of device-forming monomers.
In addition to a chromophore of the present invention and a device-forming monomer, the device materials of the present invention generally comprise a cross-linking agent. The cross-linking agent used in the device materials of this invention may be any terminally ethylenically unsaturated compound having more than one unsaturated group. Suitable cross-linking agents include, for example: ethylene glycol dimethacrylate; diethylene glycol dimethacrylate; allyl methacrylate; 1,3-propanediol dimethacrylate; 2,3-propanediol dimethacrylate; 1,6-hexanediol dimethacrylate; 1,4-butanediol dimethacrylate; CH2=C(CH3)C(=O)O-(CH2CH2O)p-C(=O)C(CH3)=CH2 where p = 1- 50; and CH2=C(CH3)C(=O)O(CH2)tO-C(=O)C(CH3)=CH2 where t = 3 -20; and their corresponding acrylates. A preferred cross-linking monomer is
7 CH2=C(CH3)C(=O)O-(CH2CH2O)p-C(=O)C(CH3)=CH2 where p is such that the number-average molecular weight is about 400, about 600, or about 1000.
Generally, the total amount of the cross-linking component is at least 0.1% by weight and, depending on the identity and concentration of the remaining components and the desired physical properties, can range to about 20% by weight. The preferred concentration range for the cross-linking component is 0.1 - 17% (w/w).
Suitable polymerization initiators for device materials containing a chromophore of the present invention include thermal initiators and photoinitiators. Preferred thermal initiators include peroxy free-radical initiators, such as t-butyl (peroxy-2-ethyl)hexanoate and di-(tert-butylcyclohexyl) peroxydicarbonate (commercially available as Perkadox 16 from Akzo Chemicals Inc., Chicago, Illinois). Initiators are typically present in an amount of about 5% (w/w) or less. The total amount of initiator is customarily not included when determining the amounts of other ingredients.
IOLs constructed of the materials of the present invention can be of any design capable of being rolled or folded into a small cross section that can fit through a relatively smaller incision. For example, the IOLs can be of what is known as a one piece or multipiece design, and comprise optic and haptic components. The optic is that portion which serves as the lens. The haptics are attached to the optic and hold the optic in its proper place in the eye. The optic and haptic(s) can be of the same or different material. A
multipiece lens is so called because the optic and the haptic(s) are made separately and then the haptics are attached to the optic. In a single piece lens, the optic and the haptics are formed out of one piece of material.
Depending on the material, the haptics are then cut, or lathed, out of the material to produce the IOL.
Generally, the total amount of the cross-linking component is at least 0.1% by weight and, depending on the identity and concentration of the remaining components and the desired physical properties, can range to about 20% by weight. The preferred concentration range for the cross-linking component is 0.1 - 17% (w/w).
Suitable polymerization initiators for device materials containing a chromophore of the present invention include thermal initiators and photoinitiators. Preferred thermal initiators include peroxy free-radical initiators, such as t-butyl (peroxy-2-ethyl)hexanoate and di-(tert-butylcyclohexyl) peroxydicarbonate (commercially available as Perkadox 16 from Akzo Chemicals Inc., Chicago, Illinois). Initiators are typically present in an amount of about 5% (w/w) or less. The total amount of initiator is customarily not included when determining the amounts of other ingredients.
IOLs constructed of the materials of the present invention can be of any design capable of being rolled or folded into a small cross section that can fit through a relatively smaller incision. For example, the IOLs can be of what is known as a one piece or multipiece design, and comprise optic and haptic components. The optic is that portion which serves as the lens. The haptics are attached to the optic and hold the optic in its proper place in the eye. The optic and haptic(s) can be of the same or different material. A
multipiece lens is so called because the optic and the haptic(s) are made separately and then the haptics are attached to the optic. In a single piece lens, the optic and the haptics are formed out of one piece of material.
Depending on the material, the haptics are then cut, or lathed, out of the material to produce the IOL.
8 In addition to IOLs, the materials of the present invention are also suitable for use in other ophthalmic devices, such as contact lenses, keratoprostheses, and corneal inlays or rings.
The invention will be further illustrated by the following examples, which are intended to be illustrative, but not limiting.
Example 1: Synthesis of (2).
2-Amino-4-(2-amino-ethyl)-phenol (1) (1 mmol) is dissolved in aqueous HCI.
The solution is cooled to 0 C and 1 mmol of NaNO2 dissolved in H20 is added slowly with stirring. The reaction mixture is maintained at 0 C for 1 hr, then NaN3 (2 mmol) dissolved in water is added dropwise with stirring. The resulting mixture is maintained at 0 C for 1 hr, then the cooling bath is removed and the mixture stirred overnight at ambient temperature. The product is extracted with ethyl acetate, washed with saturated NaHCO3 and H20. The organic phase is dried with Na2SO4, then the solvent removed under vacuum. The crude product is purified by column chromatography to yield 4-(2-amino-ethyl)-2-azido-phenol (2).
Example 2: Synthesis of (3).
A flask is flushed with N2 and charged with 2-Bromo-4-methylphenol (20 mmol) and dissolved in 1/1 Et3N/dioxane. Bis(triphenylphosphine)palladium(II) dichloride (PdCI2(PPh3)2) (0.2 mmol) is added, followed by 0.4 mmol of Cul.
Trimethylsilylacetylene (24 mmol) is added drop-wise to the reaction mixture.
The reaction mixture is stirred overnight under N2. The solvents are removed under vacuum and the resulting liquid is extracted by washing with ethyl ether. The ethyl ether extracts are combined and washed with H20, then dried over anhydrous sodium sulfate. The solvent was removed under vacuum and the product is purified by column chromatography. The purified product is placed in a N2-flushed flask and dissolved in methanol. Potassium fluoride (65 mmol) is added and the reaction stirred under a N2 blanket for 16 h. The reaction mixture is poured into CH2CI2 and extracted with H20, then dried
The invention will be further illustrated by the following examples, which are intended to be illustrative, but not limiting.
Example 1: Synthesis of (2).
2-Amino-4-(2-amino-ethyl)-phenol (1) (1 mmol) is dissolved in aqueous HCI.
The solution is cooled to 0 C and 1 mmol of NaNO2 dissolved in H20 is added slowly with stirring. The reaction mixture is maintained at 0 C for 1 hr, then NaN3 (2 mmol) dissolved in water is added dropwise with stirring. The resulting mixture is maintained at 0 C for 1 hr, then the cooling bath is removed and the mixture stirred overnight at ambient temperature. The product is extracted with ethyl acetate, washed with saturated NaHCO3 and H20. The organic phase is dried with Na2SO4, then the solvent removed under vacuum. The crude product is purified by column chromatography to yield 4-(2-amino-ethyl)-2-azido-phenol (2).
Example 2: Synthesis of (3).
A flask is flushed with N2 and charged with 2-Bromo-4-methylphenol (20 mmol) and dissolved in 1/1 Et3N/dioxane. Bis(triphenylphosphine)palladium(II) dichloride (PdCI2(PPh3)2) (0.2 mmol) is added, followed by 0.4 mmol of Cul.
Trimethylsilylacetylene (24 mmol) is added drop-wise to the reaction mixture.
The reaction mixture is stirred overnight under N2. The solvents are removed under vacuum and the resulting liquid is extracted by washing with ethyl ether. The ethyl ether extracts are combined and washed with H20, then dried over anhydrous sodium sulfate. The solvent was removed under vacuum and the product is purified by column chromatography. The purified product is placed in a N2-flushed flask and dissolved in methanol. Potassium fluoride (65 mmol) is added and the reaction stirred under a N2 blanket for 16 h. The reaction mixture is poured into CH2CI2 and extracted with H20, then dried
9 over Na2SO4, filtered and the solvent is removed under vacuum. The resulting product is purified by column chromatography to yield 2-ethynyl-4-methyl-phenol (3).
Example 3: Synthesis of (4).
A flask is charged with 100 mmol of boric acid followed by 6N HCI solution to adjust the reaction solution to a pH of 2. Once the salt dissolves, 20 mmol of o-toluidine is added to the reaction solution, followed by enough ice to reduce solution temperature to 0 C. In a separate flask, 20 mmol of sodium nitrite (NaNO2) is dissolved in ice water. The NaNO2 solution is added drop wise with constant stirring to the o-toluidine solution. The pH of the reaction solution is maintained by addition of 6N HCI. After the addition of sodium nitrite solution is complete, ice is added to maintain the 0 C reaction temperature. A 3rd flask is charged with 20 mmol of 2-ethynyl-4-methyl-phenol (3), water and 2.5 N NaOH (20 mmol), which is then added drop wise to the ice cooled reaction with constant stirring. The reaction mixture is allowed to stir for 15 min at pH 2.0 - 2.5. NaOH (2.5 N) is added in small aliquots to the reaction solution to increase the pH to 8.5. The reaction solution is allowed to warm to room temperature. Dibasic sodium phosphate solution (100 mmol) is added and the pH is adjusted to 6.0 with 6 N HCI. The product is filtered, rinsed with ice water and air dried. The product is purified by column chromatography to yield 2-ethynyl-4-methyl-6-o-tolylazo-phenol (4).
Example 4: Synthesis of (5).
A flask containing a PTFE coated stir bar is flushed with N2 and charged with 15 mmol of aryl azide (2), 15 mmol of aryl acetylene (4), N,N-dimethylformamide, 3.0 mmol of N,N,N',N",N"-pentamethyldiethylenetriamine, and 1.5 mmol of CuBr. The flask is stirred 20 h at ambient temperature. The reaction mixture is then exposed to air and purified by passing through a chromatographic alumina column. The eluent is collected and the solvent is removed under vacuum to yield product (5).
Example 5: Synthesis of (6).
A flask containing a PTFE coated stir bar is flushed with N2 and charged with mmol of amino functional triazole (5) and THF. Methacrylic acid (10 mmol) was added drop-wise to the stirring THF solution. Once the addition is 5 complete the reaction is stirred at ambient temperature for 2 hrs. The solvent is evaporated under vacuum and the crude product is purified by column chromatography. The eluent is collected and the solvent is removed under vacuum to yield product (6).
Example 3: Synthesis of (4).
A flask is charged with 100 mmol of boric acid followed by 6N HCI solution to adjust the reaction solution to a pH of 2. Once the salt dissolves, 20 mmol of o-toluidine is added to the reaction solution, followed by enough ice to reduce solution temperature to 0 C. In a separate flask, 20 mmol of sodium nitrite (NaNO2) is dissolved in ice water. The NaNO2 solution is added drop wise with constant stirring to the o-toluidine solution. The pH of the reaction solution is maintained by addition of 6N HCI. After the addition of sodium nitrite solution is complete, ice is added to maintain the 0 C reaction temperature. A 3rd flask is charged with 20 mmol of 2-ethynyl-4-methyl-phenol (3), water and 2.5 N NaOH (20 mmol), which is then added drop wise to the ice cooled reaction with constant stirring. The reaction mixture is allowed to stir for 15 min at pH 2.0 - 2.5. NaOH (2.5 N) is added in small aliquots to the reaction solution to increase the pH to 8.5. The reaction solution is allowed to warm to room temperature. Dibasic sodium phosphate solution (100 mmol) is added and the pH is adjusted to 6.0 with 6 N HCI. The product is filtered, rinsed with ice water and air dried. The product is purified by column chromatography to yield 2-ethynyl-4-methyl-6-o-tolylazo-phenol (4).
Example 4: Synthesis of (5).
A flask containing a PTFE coated stir bar is flushed with N2 and charged with 15 mmol of aryl azide (2), 15 mmol of aryl acetylene (4), N,N-dimethylformamide, 3.0 mmol of N,N,N',N",N"-pentamethyldiethylenetriamine, and 1.5 mmol of CuBr. The flask is stirred 20 h at ambient temperature. The reaction mixture is then exposed to air and purified by passing through a chromatographic alumina column. The eluent is collected and the solvent is removed under vacuum to yield product (5).
Example 5: Synthesis of (6).
A flask containing a PTFE coated stir bar is flushed with N2 and charged with mmol of amino functional triazole (5) and THF. Methacrylic acid (10 mmol) was added drop-wise to the stirring THF solution. Once the addition is 5 complete the reaction is stirred at ambient temperature for 2 hrs. The solvent is evaporated under vacuum and the crude product is purified by column chromatography. The eluent is collected and the solvent is removed under vacuum to yield product (6).
10 EXAMPLES 6- 9. Copolymerization of a chromophore with a device-forming monomer.
A vial is charged with ingredients as listed in Table 1 except for the initiator.
The solution is mixed thoroughly and de-gassed by bubbling with N2. The initiator is added and the solution is again mixed thoroughly. The solution is 1s filtered through a 0.2 micron PTFE filter and transferred to polypropylene molds. The molds are heated in a mechanical convection oven at 70 C for 1 hr, then 110 C for 2 hrs. The resulting copolymer samples are removed from the polypropylene molds and extracted in refluxing acetone for at least 3 hr, then rinsed with fresh acetone and allowed to air dry. The extracted polymer is dried under vacuum at 70 C for at least 3 hr.
A vial is charged with ingredients as listed in Table 1 except for the initiator.
The solution is mixed thoroughly and de-gassed by bubbling with N2. The initiator is added and the solution is again mixed thoroughly. The solution is 1s filtered through a 0.2 micron PTFE filter and transferred to polypropylene molds. The molds are heated in a mechanical convection oven at 70 C for 1 hr, then 110 C for 2 hrs. The resulting copolymer samples are removed from the polypropylene molds and extracted in refluxing acetone for at least 3 hr, then rinsed with fresh acetone and allowed to air dry. The extracted polymer is dried under vacuum at 70 C for at least 3 hr.
11 Table 1. Representative Copolymer Formulations Amount (% w/w) s Ingredient 6 7 8 9 PEA 65.0 80.0 0.0 65.0 PEMA 29.95 0.0 0.0 31.25 PBMA 0.0 0.0 82.15 0.0 HEMA 0.0 14.95 0.0 0.0 PEG(1000)DMA 0.0 0.0 15.0 0.0 EGDMA 0.0 0.0 1.0 0.0 BDDA 3.2 3.2 0.0 3.2 o-MTP 1.8 1.8 1.8 0.0 Chromophore (6) 0.05 0.05 0.05 0.5 Perkadox 16S 1.0 1.0 1.0 1.0 PEA = 2-phenylethyl acrylate PEMA = 2-phenylethyl methacrylate PBMA = 4-phenylbutyl methacrylate HEMA = 2-hydroxyethyl methacrylate PEG(1000)DMA = polyethylene glycol (1000) dimethacrylate EGDMA = ethylene glycol dimethacrylate BDDA = 1,4-butanediol diacrylate oMTP = o-methallyl Tinuvin P
This invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its special or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.
This invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its special or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.
12
Claims (12)
1. A chromophore of the formula wherein A=H or CH3;
X=O or NH;
n=2-6;
m=0-6; and R=H, C1-C4 alkyl, or C1-C4 alkoxy.
X=O or NH;
n=2-6;
m=0-6; and R=H, C1-C4 alkyl, or C1-C4 alkoxy.
2. The chromophore of claim 1 wherein A=CH3;
X=NH;
n=2;
m=0; and R=CH3.
X=NH;
n=2;
m=0; and R=CH3.
3. An ophthalmic device material comprising the chromophore of claim 1 and a device-forming monomer selected from the group consisting of acrylic monomers and silicone-containing monomers.
4. The ophthalmic device material of claim 3 wherein the ophthalmic device material comprises from 0.1 to 5% (w/w) of the chromophore of the formula wherein A=H or CH3;
X=O or NH;
n=2-6;
rn=0-6; and R=H, C1-C4 alkyl, or C1-C4 alkoxy.
X=O or NH;
n=2-6;
rn=0-6; and R=H, C1-C4 alkyl, or C1-C4 alkoxy.
5. The ophthalmic device material of claim 4 wherein the ophthalmic device material comprises from 0.5 to 3% (w/w) of the chromophore of the formula wherein A=H or CH3;
X=O or NH;
n=2-6;
m=0-6; and R=H, C1-C4 alkyl, or C1-C4 alkoxy.
X=O or NH;
n=2-6;
m=0-6; and R=H, C1-C4 alkyl, or C1-C4 alkoxy.
6. The ophthalmic device material of claim 3 wherein the ophthalmic device material comprises a device-forming monomer of formula [II]:
where in formula [II]:
A is H, CH3, CH2CH3, or CH2OH;
B is (CH2)m or [O(CH2)2]z;
C is (CH2)w;
m is 0-6;
z is 1-10;
Y is nothing, O, S, or NR', provided that if Y is O, S, or NR', then B is (CH2)m;
R' is H, CH3, C n'H2n'+1 (n'=1-10), iso-OC3H7, C6H5, or CH2C6H5;
w is 0-6, provided that m+w~8; and D is H, C1-C4 alkyl, C1-C4 alkoxy, C6H5, CH2C6H5 or halogen.
where in formula [II]:
A is H, CH3, CH2CH3, or CH2OH;
B is (CH2)m or [O(CH2)2]z;
C is (CH2)w;
m is 0-6;
z is 1-10;
Y is nothing, O, S, or NR', provided that if Y is O, S, or NR', then B is (CH2)m;
R' is H, CH3, C n'H2n'+1 (n'=1-10), iso-OC3H7, C6H5, or CH2C6H5;
w is 0-6, provided that m+w~8; and D is H, C1-C4 alkyl, C1-C4 alkoxy, C6H5, CH2C6H5 or halogen.
7. The ophthalmic device material of claim 6 wherein in formula [II]:
A is H or CH3;
B is (CH2)m;
m is 1-5;
Y is nothing or O;
w is 0-1; and D is H.
A is H or CH3;
B is (CH2)m;
m is 1-5;
Y is nothing or O;
w is 0-1; and D is H.
8. The ophthalmic device material of claim 7 wherein the ophthalmic device material comprises a monomer selected from the group consisting of: benzyl methacrylate;
2-phenyl ethyl methacrylate; 4-phenylbutyl methacrylate; 5-phenyl-pentyl methacrylate;
2-benzyloxyethyl methacrylate; and 3-benzyloxypropyl methacrylate; and their corresponding acrylates.
2-phenyl ethyl methacrylate; 4-phenylbutyl methacrylate; 5-phenyl-pentyl methacrylate;
2-benzyloxyethyl methacrylate; and 3-benzyloxypropyl methacrylate; and their corresponding acrylates.
9. The ophthalmic device material of claim 3 wherein the ophthalmic device material comprises a cross-linking agent.
10. An ophthalmic device comprising the ophthalmic device material of claim 3.
11. The ophthalmic device of claim 10 wherein the ophthalmic device is selected from the group consisting of an intraocular lens; a contact lens; a keratoprosthesis; and a corneal inlay or ring.
12. An intraocular lens comprising the chromophore of claim 1.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95499207P | 2007-08-09 | 2007-08-09 | |
| US60/954,992 | 2007-08-09 | ||
| PCT/US2008/072406 WO2009021085A1 (en) | 2007-08-09 | 2008-08-07 | Ophthalmic lens materials containing chromophores that absorb both uv and short wavelength visible light |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2693845A1 CA2693845A1 (en) | 2009-02-12 |
| CA2693845C true CA2693845C (en) | 2014-11-25 |
Family
ID=39832478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2693845A Expired - Fee Related CA2693845C (en) | 2007-08-09 | 2008-08-07 | Ophthalmic lens materials containing chromophores that absorb both uv and short wavelength visible light |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7728051B2 (en) |
| EP (1) | EP2176243B1 (en) |
| JP (1) | JP5324575B2 (en) |
| AR (1) | AR067890A1 (en) |
| AT (1) | ATE497952T1 (en) |
| AU (1) | AU2008283862B2 (en) |
| CA (1) | CA2693845C (en) |
| DE (1) | DE602008004920D1 (en) |
| ES (1) | ES2358308T3 (en) |
| TW (1) | TWI435915B (en) |
| WO (1) | WO2009021085A1 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602008002426D1 (en) * | 2007-04-30 | 2010-10-14 | Alcon Inc | UV ABSORBER FOR GLASSES OF GLASSES |
| TW200916531A (en) * | 2007-08-09 | 2009-04-16 | Alcon Inc | Ophthalmic lens materials containing chromophores that absorb both UV and short wavelength visible light |
| WO2009102454A1 (en) * | 2008-02-12 | 2009-08-20 | Aaren Scientific Inc. | Ophthalmic lens having a yellow dye light blocking component |
| US7803359B1 (en) | 2008-05-06 | 2010-09-28 | Alcon, Inc. | UV-absorbers for ophthalmic lens materials |
| US8043607B2 (en) | 2008-07-15 | 2011-10-25 | Novartis Ag | UV-absorbers for ophthalmic lens materials |
| US8236053B1 (en) | 2008-10-08 | 2012-08-07 | Novartis Ag | 2-amino benzophenone UV-absorbers for ophthalmic lens materials |
| TWI453199B (en) | 2008-11-04 | 2014-09-21 | Alcon Inc | Uv/visible light absorbers for ophthalmic lens materials |
| TWI487690B (en) | 2009-07-06 | 2015-06-11 | Alcon Inc | Visible light absorbers for ophthalmic lens materials |
| TWI464151B (en) * | 2009-07-06 | 2014-12-11 | Alcon Inc | Uv/visible light absorbers for ophthalmic lens materials |
| TWI473629B (en) * | 2010-01-18 | 2015-02-21 | Alcon Inc | Visible light absorbers for ophthalmic lens materials |
| CN102971553A (en) | 2010-04-15 | 2013-03-13 | 迪姆肯公司 | Two-array planetary gear system with flexpins and helical gearing |
| TW201311621A (en) | 2011-08-15 | 2013-03-16 | Novartis Ag | UV-absorbers for ophthalmic lens materials |
| US8585938B1 (en) | 2012-03-30 | 2013-11-19 | Novartis Ag | UV-absorbers for ophthalmic lens materials |
| US10935695B2 (en) | 2018-03-02 | 2021-03-02 | Johnson & Johnson Vision Care, Inc. | Polymerizable absorbers of UV and high energy visible light |
| US11543683B2 (en) | 2019-08-30 | 2023-01-03 | Johnson & Johnson Vision Care, Inc. | Multifocal contact lens displaying improved vision attributes |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1356434A (en) * | 1970-06-17 | 1974-06-12 | Gaf Corp | Triazole compounds and cosmetic compositions containing them |
| JPS4963681A (en) * | 1972-10-20 | 1974-06-20 | ||
| US4390676A (en) | 1976-11-15 | 1983-06-28 | Schering Corporation | Ultraviolet absorbing lenses |
| US4611061A (en) | 1984-03-26 | 1986-09-09 | Iolab Corporation | 2'-hydroxy-5'-(hydroxyalkyl)phenyl-2H-benzotriazoles |
| US4528311A (en) | 1983-07-11 | 1985-07-09 | Iolab Corporation | Ultraviolet absorbing polymers comprising 2-hydroxy-5-acrylyloxyphenyl-2H-benzotriazoles |
| NZ208751A (en) * | 1983-07-11 | 1987-04-30 | Iolab Corp | 2-hydroxy-5-acrylyloxyalkylphenyl-2h-benzotriazole derivatives and polymers and copolymers thereof and use as uv absorbing additives in polymer compositions |
| DE3439483A1 (en) * | 1984-10-27 | 1986-05-07 | Röhm GmbH, 6100 Darmstadt | RADICALLY POLYMERIZABLE UV ABSORBER, METHOD FOR PRODUCING IT AND ITS POLYMERS |
| SE8503522D0 (en) | 1985-07-19 | 1985-07-19 | Pharmacia Ab | UV-ABSORBING LENS MATERIAL |
| US4716234A (en) * | 1986-12-01 | 1987-12-29 | Iolab Corporation | Ultraviolet absorbing polymers comprising 2-(2'-hydroxy-5'-acryloyloxyalkoxyphenyl)-2H-benzotriazole |
| US4803254A (en) | 1987-03-11 | 1989-02-07 | Iolab Corporation | Vinylsilylalkoxy arylbenzotriazole compounds and UV absorbing compositions made therefrom |
| JP2604799B2 (en) | 1988-05-27 | 1997-04-30 | 株式会社メニコン | Intraocular lens material |
| JP2753067B2 (en) * | 1988-09-16 | 1998-05-18 | 株式会社メニコン | Polymerizable ultraviolet absorbing dye for ophthalmic lens and ophthalmic lens material using the same |
| US5290892A (en) | 1990-11-07 | 1994-03-01 | Nestle S.A. | Flexible intraocular lenses made from high refractive index polymers |
| JP2685980B2 (en) | 1990-11-26 | 1997-12-08 | 株式会社メニコン | UV absorbing intraocular lens |
| US5331073A (en) | 1992-11-09 | 1994-07-19 | Allergan, Inc. | Polymeric compositions and intraocular lenses made from same |
| BR9406280A (en) | 1993-04-22 | 1996-02-06 | Jessen Wesley Corp | UV-absorbing benzotriazois having a styrene group |
| US5470932A (en) * | 1993-10-18 | 1995-11-28 | Alcon Laboratories, Inc. | Polymerizable yellow dyes and their use in opthalmic lenses |
| EP0774983B1 (en) | 1995-06-07 | 2002-12-04 | Alcon Laboratories, Inc. | Improved high refractive index ophthalmic lens materials |
| US6166218A (en) | 1996-11-07 | 2000-12-26 | Ciba Specialty Chemicals Corporation | Benzotriazole UV absorbers having enhanced durability |
| JP3805853B2 (en) | 1997-03-13 | 2006-08-09 | 株式会社メニコン | Polymerizable dye and colored ophthalmic lens material using the same |
| US6036891A (en) * | 1998-05-11 | 2000-03-14 | Pharmacia & Upjohn | Polymerizable hydrophilic ultraviolet light absorbing monomers |
| US6244707B1 (en) | 1998-07-21 | 2001-06-12 | Wesley Jessen Corporation | UV blocking lenses and material containing benzotriazoles and benzophenones |
| US6320008B2 (en) | 1999-02-17 | 2001-11-20 | Menicon Co., Ltd. | Polymeric colorant and colored material for ocular lens using the colorant |
| JP4149068B2 (en) | 1999-03-02 | 2008-09-10 | 株式会社メニコン | Ophthalmic lens material |
| JP3449406B2 (en) | 1999-04-07 | 2003-09-22 | Ｈｏｙａヘルスケア株式会社 | Novel pyrazolone compound and ophthalmic plastic lens using the same |
| JP5459816B2 (en) * | 1999-09-07 | 2014-04-02 | アルコン，インコーポレイテッド | Foldable ophthalmic and otolaryngological device materials |
| US20020042653A1 (en) | 1999-11-23 | 2002-04-11 | Copeland Victor L. | Blue blocking intraocular lens implant |
| DE60103597T2 (en) | 2000-03-22 | 2005-06-09 | Menicon Co., Ltd., Nagoya | MATERIAL FOR AN OKULAR LENS |
| JP4210719B2 (en) | 2001-09-14 | 2009-01-21 | スター・ジャパン株式会社 | Ophthalmic lens |
| US6908978B2 (en) | 2001-11-02 | 2005-06-21 | Bausch & Lomb Incorporated | High refractive index polymeric siloxysilane compositions |
| US6762271B2 (en) | 2001-11-02 | 2004-07-13 | Bausch & Lomb Incorporated | High refractive index aromatic-based silyl monomers |
| WO2003101972A1 (en) | 2002-05-30 | 2003-12-11 | The Scripps Research Institute | Copper-catalysed ligation of azides and acetylenes |
| US6852793B2 (en) | 2002-06-19 | 2005-02-08 | Bausch & Lomb Incorporated | Low water content, high refractive index, flexible, polymeric compositions |
| DE60320556T2 (en) | 2002-07-16 | 2009-05-28 | Alcon Inc. | MATERIALS FOR OPHTHALMIC AND OTORHINOLARYNGOLOGICAL DEVICE |
| JP4233320B2 (en) | 2002-12-20 | 2009-03-04 | 株式会社ニデック | Colorant for ophthalmic lens, and colored ophthalmic lens using the colorant |
| JP2005053058A (en) | 2003-08-04 | 2005-03-03 | Fuji Photo Film Co Ltd | Optical information recording medium and information recording method |
| US6872793B1 (en) | 2003-08-07 | 2005-03-29 | Alcon, Inc. | Ophthalmic and otorhinolaryngological device materials |
| US7098283B2 (en) | 2003-09-08 | 2006-08-29 | Bausch & Lomb Incorporated | Reactive yellow dyes useful for ocular devices |
| EP1694721B1 (en) | 2003-11-05 | 2013-10-09 | Benz Research and Development Corporation | Materials for making hydrophobic intraocular lens |
| US7278737B2 (en) | 2004-04-30 | 2007-10-09 | Advanced Medical Optics, Inc. | Ophthalmic devices having a highly selective violet light transmissive filter and related methods |
| US7381762B2 (en) | 2004-08-20 | 2008-06-03 | Milliken & Company | Ultraviolet light (UV) absorbing compounds and compositions containing UV absorbing compounds |
| JP4532243B2 (en) | 2004-11-10 | 2010-08-25 | 株式会社ニデック | Colorant for ophthalmic lens and colored ophthalmic lens material using the colorant |
| US20060115516A1 (en) | 2004-11-22 | 2006-06-01 | Pearson Jason C | Copolymerizable methine and anthraquinone compounds and articles containing them |
| ATE499620T1 (en) | 2004-11-22 | 2011-03-15 | Abbott Medical Optics Inc | COPOLYMERIZABLE AZO COMPOUNDS AND ARTICLES THEREOF |
| CN1727338A (en) | 2004-12-27 | 2006-02-01 | 常州华钛化学有限公司 | Compound in benzotriazole category possessing alkenyl ester type structure, and preparation method |
| US20060197067A1 (en) | 2005-03-04 | 2006-09-07 | Erning Xia | Radiation-absorbing materials, ophthalmic compositions containing same, and method of treating ophthalmic devices |
| JP4618640B2 (en) * | 2005-03-14 | 2011-01-26 | Ｈｏｙａ株式会社 | (Meth) acrylate copolymer and soft intraocular lens |
| US20060252850A1 (en) | 2005-05-04 | 2006-11-09 | Bausch & Lomb Incorporated | Radiation-absorbing polymeric materials and ophthalmic devices comprising same |
| US20070092830A1 (en) | 2005-10-24 | 2007-04-26 | Bausch & Lomb Incorporated | Polymeric radiation-absorbing materials and ophthalmic devices comprising same |
| US20070092831A1 (en) | 2005-10-24 | 2007-04-26 | Bausch & Lomb Incorporated | Radiation-absorbing polymeric materials and ophthalmic devices comprising same |
| JP5448166B2 (en) | 2006-10-13 | 2014-03-19 | アルコン，インコーポレイテッド | Intraocular lens with unique blue-purple cut-off and blue light transmission characteristics |
| ES2699166T3 (en) | 2007-03-05 | 2019-02-07 | Benz Res And Development Corporation | Light filters that comprise a chromophore found in nature and its derivatives |
| DE602008002426D1 (en) | 2007-04-30 | 2010-10-14 | Alcon Inc | UV ABSORBER FOR GLASSES OF GLASSES |
| JP2009013148A (en) | 2007-07-03 | 2009-01-22 | Shipro Kasei Kaisha Ltd | Chemical modification to bis type structure by adipoyl dichloride, isophthaloyl dichloride or terephthaloyl dichloride of benzotriazole-based ultraviolet light absorbent having hydroxymethyl group |
-
2008
- 2008-08-05 TW TW097129631A patent/TWI435915B/en not_active IP Right Cessation
- 2008-08-07 US US12/187,495 patent/US7728051B2/en active Active
- 2008-08-07 AT AT08827051T patent/ATE497952T1/en not_active IP Right Cessation
- 2008-08-07 AU AU2008283862A patent/AU2008283862B2/en not_active Ceased
- 2008-08-07 JP JP2010520296A patent/JP5324575B2/en active Active
- 2008-08-07 EP EP08827051A patent/EP2176243B1/en active Active
- 2008-08-07 ES ES08827051T patent/ES2358308T3/en active Active
- 2008-08-07 WO PCT/US2008/072406 patent/WO2009021085A1/en active Application Filing
- 2008-08-07 CA CA2693845A patent/CA2693845C/en not_active Expired - Fee Related
- 2008-08-07 DE DE602008004920T patent/DE602008004920D1/en active Active
- 2008-08-08 AR ARP080103475A patent/AR067890A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200916534A (en) | 2009-04-16 |
| JP2010535904A (en) | 2010-11-25 |
| CA2693845A1 (en) | 2009-02-12 |
| JP5324575B2 (en) | 2013-10-23 |
| AU2008283862B2 (en) | 2012-12-06 |
| TWI435915B (en) | 2014-05-01 |
| AU2008283862A1 (en) | 2009-02-12 |
| AR067890A1 (en) | 2009-10-28 |
| ATE497952T1 (en) | 2011-02-15 |
| DE602008004920D1 (en) | 2011-03-24 |
| US20090043007A1 (en) | 2009-02-12 |
| EP2176243B1 (en) | 2011-02-09 |
| US7728051B2 (en) | 2010-06-01 |
| ES2358308T3 (en) | 2011-05-09 |
| WO2009021085A1 (en) | 2009-02-12 |
| EP2176243A1 (en) | 2010-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2693845C (en) | Ophthalmic lens materials containing chromophores that absorb both uv and short wavelength visible light | |
| AU2008245533B2 (en) | UV-absorbers for ophthalmic lens materials | |
| US7781571B2 (en) | Ophthalmic lens materials containing chromophores that absorb both UV and short wavelength visible light | |
| KR101592448B1 (en) | Uv/visible light absorbers for ophthalmic lens materials | |
| JP5732456B2 (en) | Visible light absorbers for ophthalmic lens materials | |
| JP5758407B2 (en) | Visible light absorbers for ophthalmic lens materials | |
| US20100207068A1 (en) | Process for producing purified synthesis gas from synthesis gas comprising trace amounts of sulphur contaminants with a metal-organic framework | |
| TW201311621A (en) | UV-absorbers for ophthalmic lens materials |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130619 |
|
| MKLA | Lapsed |
Effective date: 20220301 |
|
| MKLA | Lapsed |
Effective date: 20200831 |